Gemcitabine

證據等級: L5

預測適應症: 10 個

Gemcitabine: From Pancreatic Cancer & Solid Tumors to Female Breast Carcinoma

One-Sentence Summary

Gemcitabine is a deoxycytidine nucleoside analogue antineoplastic agent, established globally as standard-of-care chemotherapy for pancreatic cancer, non-small cell lung cancer, bladder cancer, and other solid tumors. The TxGNN model predicts it may be effective for Female Breast Carcinoma with a prediction score of 99.98%, supported by multiple Phase III clinical trials and 20 publications — and notably, the FDA approved gemcitabine + paclitaxel for HER2-negative metastatic breast cancer as early as 2004, making this one of the most evidence-rich repurposing candidates in the dataset.

Quick Overview

Item	Content
Original Indication	Pancreatic cancer, NSCLC, bladder cancer, ovarian cancer (established global approvals; no Health Canada DINs captured in current dataset)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.98%
Evidence Level	L1
Canada Market Status	Not Marketed (0 DINs on record)
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Gemcitabine (2′,2′-difluorodeoxycytidine) is a nucleoside analogue that exerts cytotoxicity via two complementary mechanisms after intracellular phosphorylation to its active triphosphate form (dFdCTP): (1) inhibition of ribonucleotide reductase, depleting the deoxyribonucleotide pool needed for DNA replication; and (2) incorporation into elongating DNA strands, causing “masked” chain termination that evades proofreading by DNA polymerase. This self-potentiating dual action makes gemcitabine especially potent against rapidly proliferating tumor cells. While formal MOA data is not available in the current dataset, the mechanistic rationale is well-established in published literature and referenced within the evidence pack’s repurposing rationale.

Breast cancer — particularly triple-negative (TNBC) and HER2-positive subtypes — is characterized by high proliferative indices and heavy reliance on continuous DNA synthesis, making tumor cells directly vulnerable to gemcitabine’s DNA replication blockade. The mechanistic synergy with taxanes is especially well-characterized: paclitaxel arrests cells at the G2/M boundary by stabilizing microtubules, while gemcitabine blocks S-phase DNA synthesis, creating a two-pronged attack on the cell cycle at distinct checkpoints. This complementary mechanism led to FDA approval of gemcitabine + paclitaxel for HER2-negative metastatic breast cancer in 2004, based on Phase III data demonstrating superior progression-free survival over paclitaxel monotherapy.

The breadth of clinical investigation in breast cancer is remarkable: multiple large Phase III trials (including trials with n=4,894 and n=1,206) have evaluated gemcitabine across neoadjuvant, adjuvant, and metastatic settings. Combinations with trastuzumab, pertuzumab, carboplatin, and bevacizumab have all been explored in Phase II studies, collectively indicating that gemcitabine’s activity in breast cancer is not setting-specific but spans multiple clinical contexts. The TxGNN score of 99.98% accurately reflects this depth of biological and clinical corroboration.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00093795	Phase III	Completed	4,894	Adjuvant trial in node-positive breast cancer comparing three regimens, one of which (dose-dense AC→paclitaxel+gemcitabine) directly evaluates gemcitabine in the adjuvant breast cancer setting; the largest gemcitabine breast cancer trial on record
NCT00408408	Phase III	Unknown	1,206	Large randomized neoadjuvant trial examining whether adding gemcitabine (or capecitabine) to docetaxel before AC chemotherapy (±bevacizumab) improves pathologic complete response (pCR) in palpable, operable breast cancer; includes biomarker analyses to predict pCR
NCT00039546	Phase III	Unknown	~800	tAnGo trial: randomized comparison of paclitaxel + epirubicin + cyclophosphamide ±gemcitabine as adjuvant therapy in ER/PgR-poor early breast cancer after surgery
NCT00070278	Phase III	Unknown	800	Randomized neoadjuvant trial of sequential epirubicin/cyclophosphamide → paclitaxel ±gemcitabine in poor-risk early breast cancer; directly targets the neoadjuvant setting
NCT00440622	Phase III	Terminated	90	Randomized comparison of gemcitabine+trastuzumab vs. capecitabine+trastuzumab in pretreated HER2-positive metastatic breast cancer; terminated early (underpowered, n=90) before reaching the primary endpoint
NCT01881230	Phase II/III	Completed	191	Randomized study of nab-paclitaxel+gemcitabine or nab-paclitaxel+carboplatin vs. gemcitabine+carboplatin as first-line treatment in triple-negative metastatic breast cancer; directly addresses the TNBC subtype
NCT01352494	Phase II	Unknown	99	Multi-center neoadjuvant trial evaluating docetaxel+gemcitabine in locally advanced breast cancer; assesses tumor response rate in the pre-surgical setting
NCT02252887	Phase II	Completed	45	Gemcitabine + trastuzumab + pertuzumab in previously treated HER2-positive metastatic breast cancer that progressed on prior anti-HER2 therapy (T-DM1, trastuzumab, or lapatinib); evaluates gemcitabine as a re-induction backbone
NCT00462865	Phase II	Terminated	18	Adjuvant gemcitabine/capecitabine + bevacizumab in high-risk early breast cancer with residual disease after neoadjuvant chemotherapy; terminated early due to slow accrual
NCT00003540	Phase II	Completed	30	Single-agent gemcitabine in women with metastatic breast cancer previously treated with doxorubicin and paclitaxel; one of the earliest studies establishing gemcitabine’s single-agent activity in this setting

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15685819	2004	Systematic Review (with RCT data)	Oncology	Comprehensive synthesis of gemcitabine+paclitaxel in metastatic breast cancer; 52% objective response rate (114/221 patients) across Phase II/III trials; provided the evidentiary basis supporting FDA approval of this combination
40779028	2025	Phase I/II Clinical Study	Breast Cancer Res Treat	Phase I trial of mifepristone+carboplatin+gemcitabine in advanced breast cancer; rationale based on glucocorticoid receptor (GR) antagonism enhancing gemcitabine-induced apoptosis in GR-positive breast cancer cells
38262235	2024	Phase I Trial	Gynecol Oncol	Mirvetuximab soravtansine+gemcitabine in FRα-positive triple-negative breast cancer; determined MTD and recommended Phase 2 dose; confirms gemcitabine’s continued role in novel combination strategies for TNBC
25398698	2015	Prospective Cohort / Phase II	Cancer Chemother Pharmacol	Biweekly docetaxel+gemcitabine+bevacizumab in pretreated HER2-negative metastatic breast cancer; demonstrated activity and acceptable tolerability as salvage chemotherapy
15685824	2004	Translational/Clinical	Oncology	Characterized synergistic interactions between gemcitabine, trastuzumab, and platinum salts in HER2-overexpressing breast cancer cell lines; supported use of gemcitabine as a cardiotoxicity-sparing alternative to anthracyclines in HER2+ disease
14768404	2003	Narrative Review	Oncology	Review of gemcitabine combinations with anthracyclines and taxanes in advanced breast cancer; overall response rates up to 94% reported with triplet regimens, though toxicity management is critical
15685821	2004	Clinical Review	Oncology	Review of gemcitabine+platinum combinations in metastatic breast cancer after anthracycline/taxane failure; established gemcitabine+cisplatin or carboplatin as an active second-line doublet with meaningful response rates
12138397	2002	Review	Semin Oncol	Early summary of ~20 Phase II trials confirming gemcitabine’s single-agent activity (16–37% response rate) in metastatic breast cancer; combination regimens with platinums, taxanes, vinorelbine, and anthracyclines showed further enhanced activity
15685820	2004	Review	Oncology	Synthesis of gemcitabine+docetaxel combinations in metastatic breast cancer; standard dosing of gemcitabine 900–1,000 mg/m² on days 1+8 with docetaxel 75–100 mg/m² Q3W established as an active regimen
19856651	2009	Phase II / Dose-Finding	Tumori	Multi-center Phase II of weekly docetaxel+gemcitabine as first-line treatment for metastatic breast cancer; evaluated weekly scheduling to preserve quality of life while maintaining efficacy in anthracycline-pretreated patients

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Deoxycytidine nucleoside analogue (antimetabolite class)
Myelosuppression Risk	High — neutropenia and thrombocytopenia are the primary dose-limiting toxicities; risk is amplified in combination regimens (e.g., with platinum, taxanes)
Emetogenicity Classification	Low to Moderate (gemcitabine monotherapy carries minimal emetic risk; combination regimens containing platinum or anthracyclines elevate emetogenicity to moderate–high)
Monitoring Items	CBC with differential before each cycle; liver function tests (AST, ALT, bilirubin); renal function (creatinine, eGFR); pulmonary status (dyspnea, radiographic changes if symptoms arise)
Handling Protection	Must follow cytotoxic drug handling regulations; closed-system drug transfer devices (CSTDs) recommended for preparation and administration; appropriate PPE (gloves, gown, eye protection) required

Safety Considerations

Formal safety data (warnings, contraindications, drug interactions) is not available in the current dataset. Please refer to the package insert for complete safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple large Phase III randomized trials (including n=4,894 and n=1,206) directly evaluate gemcitabine-containing regimens across breast cancer settings, and the FDA approved gemcitabine+paclitaxel for HER2-negative metastatic breast cancer in 2004 — establishing L1-level evidence that the TxGNN prediction correctly identifies a clinically validated repurposing opportunity. The primary guardrail is the absence of Health Canada regulatory records and incomplete safety documentation in the current dataset.

To proceed, the following is needed:

Regulatory verification: Confirm Health Canada approval status — gemcitabine (brand: Gemzar; generics widely available) is likely approved in Canada but is absent from the current regulatory dataset; DIN search on the Health Canada Drug Product Database is required
Safety data gap closure: Obtain product monograph from Health Canada or TFDA to complete the S1 safety screening (currently blocked by DG001 — key warnings/contraindications not captured)
MOA documentation (DG002): Retrieve full MOA data from DrugBank API to formalize mechanism-of-action section and support indication-linkage analysis
Subtype stratification: Define the target patient population more precisely (TNBC, HER2+, or HR+/HER2−), as optimal combination partners and dosing schedules differ materially across subtypes
Combination partner DDI review: Assess drug-drug interaction profile for planned combination agents (paclitaxel, carboplatin, trastuzumab, bevacizumab) before clinical application
Dose-adjustment protocols: Document renal and hepatic dose-reduction thresholds for Canadian clinical implementation guidelines
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.